An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy

Phase 2 Completed 421 enrolled SK Life Science, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of the novel compound RWJ-333369 in reducing the frequency of seizures in patients with epilepsy.

Timeline

Start: 2005-05
Primary completion: 2010-06
Completion: 2010-06

Publications

Faught E, Holmes GL, Rosenfeld WE, Novak G, Neto W, Greenspan A, Schmitt J, Yuen E, Reines S, Haas M. Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures. Neurology. 2008 Nov 11;71(20):1586-93. doi: 10.1212/01.wnl.0000334751.89859.7f.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carisbamate	Small molecule	200 mg	Oral
Subject	Carisbamate	Small molecule	600 mg	Oral

An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy

Summary

Timeline

Publications

Drugs

Indications